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Background: In 2005 in England, universal Bacillus 
Calmette–Guérin (BCG) vaccination of school-age 
children was replaced by targeted BCG vaccination of 
high-risk neonates. Aim: Estimate the impact of the 
2005 change in BCG policy on tuberculosis (TB) inci-
dence rates in England. Methods: We conducted an 
observational study by combining notifications from 
the Enhanced Tuberculosis Surveillance system, with 
demographic data from the Labour Force Survey to 
construct retrospective cohorts relevant to both the 
universal and targeted vaccination between 1 January 
2000 and 31 December 2010. We then estimated inci-
dence rates over a 5-year follow-up period and used 
regression modelling to estimate the impact of the 
change in policy on TB. Results: In the non-United 
Kingdom (UK) born, we found evidence for an asso-
ciation between a reduction in incidence rates and the 
change in BCG policy (school-age incidence rate ratio 
(IRR): 0.74; 95% credible interval (CrI): 0.61 to 0.88 and 
neonatal IRR: 0.62; 95%CrI: 0.44 to 0.88). We found 
some evidence that the change in policy was associ-
ated with an increase in incidence rates in the UK born 
school-age population (IRR: 1.08; 95%CrI: 0.97 to 1.19) 
and weaker evidence of an association with a reduc-
tion in incidence rates in UK born neonates (IRR: 0.96; 
95%CrI: 0.82 to 1.14). Overall, we found that the change 
in policy was associated with directly preventing 385 
(95%CrI: −105 to 881) cases. Conclusions: Withdrawing 
universal vaccination at school age and targeting vac-
cination towards high-risk neonates was associated 
with reduced incidence of TB. This was largely driven 
by reductions in the non-UK born with cases increas-
ing in the UK born.
Introduction
In 2005, England changed its Bacillus Calmette–Guérin 
(BCG) vaccination policy against tuberculosis (TB) from 
a universal programme aimed at 13 and 14 year olds to 
a targeted programme aimed at high-risk neonates. 
High-risk babies are identified by local TB incidence 
and by the parents’ and grandparents’ country of ori-
gin. The change in policy was motivated by evidence 
of reduced TB transmission [1-3], high effectiveness of 
the BCG vaccine in young children [4-6] and variable 
effectiveness in adults [7]. Little work has been done 
to evaluate the impact of this change in vaccination 
policy.
Globally, several countries with low TB incidence have 
moved from universal vaccination, either of those at 
school age or neonates, to targeted vaccination of 
neonates considered at high risk of TB [7]. In Sweden, 
which discontinued universal vaccination of neonates 
in favour of targeted vaccination of those at high risk, 
incidence rates in Swedish-born children increased 
slightly after the change in policy [8]. In France, which 
also switched from universal vaccination of children 
to targeted vaccination of those at high risk, a study 
found that targeted vaccination may have reduced cov-
erage in those most at risk [9].
The number of TB notifications in England increased 
from 6,929 in 2004 to 8,280 in 2011 but has since 
declined to 5,137 in 2017 [1]. A recent study found that 
this reduction may be linked to improved TB interven-
tions [10]. Directly linking trends in TB incidence to 
transmission is complex because after an initial infec-
tion an individual may either develop active disease, 
or enter a latent stage, which then may later develop 
into active disease. Incidence in children is a proxy of 
TB transmission, because any active TB disease in this 
population is attributable to recent transmission. Using 
this approach it is thought that TB transmission has 
been falling in England since 2011, a notion supported 
by strain typing [1]. Nevertheless, the effect of the 
change in BCG policy, which is likely to have reduced 
incidence rates in children, has not been assessed.
Although the long-term effects of BCG vaccination 
such as reducing the reactivation of latent cases and 
decreasing onwards transmission are not readily 
detectable over short time scales, the direct effects of 
vaccination on incidence rates can be estimated in vac-
cinated populations, when compared with comparable 
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Figure 
Mean incidence rates per 100,000 population, with 95% confidence intervals for each retrospective cohorta studied to assess 
the effect of the 2005 change in BCG policy, stratified by the vaccination policy and UK birth status, England, 2000–2015
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a Cohort definitions figure in Table 1.
The top and bottom panels are on different scales in order to highlight trends in incidence rates over time.
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unvaccinated populations [11]. Here, we aimed to esti-
mate the impact of the 2005 change in BCG policy on 
incidence rates in England, in both the United Kingdom 
(UK) and non-UK born populations, directly affected by 
it.
Methods
Data sources
Data on all notifications from the Enhanced 
Tuberculosis Surveillance (ETS) system from 1 January 
2000 to 31 December 2015 were obtained from Public 
Health England (PHE). The ETS is maintained by PHE 
and contains demographic, clinical and microbiologi-
cal data on all notified cases in England. A descriptive 
analysis of TB epidemiology in England is published 
each year, which fully details data collection and clean-
ing [1]. Tuberculosis is highly heterogeneous in England 
with the majority of cases occurring in urban, non-UK 
born populations. The yearly PHE report contains more 
descriptive detail [1].
We obtained yearly population estimates from the April 
to June Labour Force Survey (LFS) for years 2000 to 2015. 
The LFS is a household study of the employment cir-
cumstances of the UK population, which provides the 
official measures of employment and unemployment 
in the UK. It is also used to study population demo-
graphics such as ethnicity, country of birth and age. 
Reporting practices have changed with time so the 
appropriate variables for age, country of origin, coun-
try of birth, and survey weight were extracted from 
each yearly extract, standardised and combined into a 
single dataset.
Constructing retrospective cohorts
We constructed retrospective cohorts of TB cases and 
individuals using the ETS and the LFS. Tuberculosis 
cases were extracted from the ETS based on date of 
birth and date of TB notification.
Cohort 1: individuals aged 14 years between 2000 and 
2004, who were notified with TB while aged between 
14 and 19 years.
Comparison cohort 1: individuals aged 14 years 
between 2005 and 2010, who were notified with TB 
while aged between 14 and 19 years.
Cohort 2: individuals born between 2005 and 2010, 
who were notified with TB while aged 0 to 5 years.
Comparison cohort 2: individuals born between 2000 
and 2004, who were notified with TB while aged 
0 to 5 years.
Cohorts were stratified by vaccination programme 
using age criteria and then stratified further by whether 
the scheme was in place during the time period they 
entered the study. Each cohort was further stratified by 
UK birth status, with both non-UK born and UK born 
cases assumed to have been exposed to England’s 
vaccination policy. Corresponding population cohorts 
were calculated using the LFS population estimates, 
resulting in eight population level cohorts, each with 
5 years of follow-up (Table 1).
Statistical methods overview
We estimated incidence rates (with 95% confidence 
intervals (CI)) by year, age and place of birth as (num-
ber of cases) divided by (number of individuals of cor-
responding age). UK birth status was incomplete, with 
some evidence of a missing not at random mechanism. 
We imputed the missing data using a gradient boost-
ing method (GBM; see  Supplement). We then used a 
descriptive analysis to describe the observed trends 
in age-specific incidence rates over the study period, 
comparing incidence rates in the study populations rel-
evant to both vaccination programmes before and after 
the change in BCG policy.
Table 1
Summary of relevance and eligibility criteria of cohorts studied to assess the effect of the 2005 change in BCG policy, 
England, 2000–2010.
Cohort Vaccination programme
Eligible for the 
programmea Birth status
Age in years at 
study entry Year of study entry
Cohort 1 Universal Yes UK born 14 2000–2004
Comparison cohort 1 Universal No UK born 14 2005–2010
Cohort 1 Universal Yes Non-UK born 14 2000–2004
Comparison cohort 1 Universal No Non-UK born 14 2005–2010
Cohort 2 Targeted Yes UK born Birth 2005–2010
Comparison cohort 2 Targeted No UK born Birth 2000–2004
Cohort 2 Targeted Yes Non-UK born Birth 2005–2010
Comparison cohort 2 Targeted No Non-UK born Birth 2000–2004
BCG: Bacillus Calmette–Guérin; UK: United Kingdom.
a Eligible signifies that the cohort fit the criteria for the vaccination programme and entered the study during the time period it was in 
operation not that the cohort was vaccinated by the vaccination programme.
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We calculated incidence rate ratios (IRRs) with 
95% credible intervals (CrIs) for the change in incidence 
rates associated with the change in BCG vaccination 
policy (modelled as a binary breakpoint at the start of 
2005) for both the UK born and non-UK born popula-
tions that were relevant for the universal programme 
and for the targeted programme, using a range of mod-
els. We considered the following covariates: age [1,7], 
incidence rates in both the UK born and non-UK born 
who were not in the age group of interest [1] and year 
of study entry (as a random intercept). We evaluated a 
range of models using a statistically rigorous criterion 
that accounted for model fit and complexity, for model 
selection.
Statistical modelling details
We first investigated a univariable Poisson model, 
followed by combinations of covariates (Supplement 
Table S1). We also investigated a negative binomial 
model, adjusting for the same covariates as in the 
best fitting Poisson model. The models were estimated 
with a Bayesian approach using Markov Chain Monte 
Carlo (MCMC) with default weakly informative priors 
(Supplement). Model fit, penalised by model complex-
ity, was assessed using the leave one out cross vali-
dation information criterion (LOOIC) and its standard 
error [12]. Models were ranked by goodness of fit, using 
their LOOIC, with a smaller LOOIC indicating a better 
fit to the data after adjusting for the complexity of the 
Table 2
Incidence rate ratios of tuberculosis in the UK born and non-UK born cohorts relevant to the universal school-
age BCG vaccination scheme, using the best fitting modelsa as determined by comparison of the LOOIC, England, 
2000–2015
Variable
IRR (95% CrI)
UK born Non-UK born
Policy changeb
Pre-change Reference Reference
Post-change 1.08 (0.97 to  1.19) 0.74 (0.61 to  0.88)
Age in years
14 Reference Reference
15 1.18 (0.98 to 1.42) 1.03 (0.87 to 1.22)
16 1.24 (1.03 to 1.50) 1.25 (1.07 to 1.47)
17 1.59 (1.33 to 1.91) 1.40 (1.19 to 1.63)
18 1.92 (1.60 to 2.30) 1.47 (1.26 to 1.73)
19 1.80 (1.49 to 2.17) 1.47 (1.24 to 1.73)
Incidence rate
UK born incidence rate (per standard deviation) 1.08 (1.03 to 1.14) NA
Non-UK born incidence rate (per standard deviation) NA 1.11 (1.03 to 1.19)
Year of study eligibility, group level
Intercept (standard deviation) NA 1.13 (1.05 to 1.26)
Year of study eligibility, individual level
2000 NA 1.10 (0.96 to 1.29)
2001 NA 1.06 (0.93 to 1.24)
2002 NA 1.07 (0.94 to 1.25)
2003 NA 0.90 (0.76 to 1.03)
2004 NA 0.89 (0.75 to 1.02)
2005 NA 0.98 (0.85 to 1.12)
2006 NA 1.13 (0.99 to 1.33)
2007 NA 1.04 (0.91 to 1.20)
2008 NA 0.96 (0.83 to 1.09)
2009 NA 0.95 (0.81 to 1.08)
2010 NA 0.96 (0.82 to 1.11)
BCG: Bacillus Calmette–Guérin; CrI: credible interval; IRR: incidence rate ratio; LOOIC: leave one out cross validation information criterion; SE: 
standard error; NA: not applicable (i.e. model terms were not included in the given cohort); UK: United Kingdom.
a The best fitting model for the UK born was a negative binomial model adjusting with fixed effects for the change in policy, age and incidence 
rates in the UK born (Model 7; Supplement Table S1). For the non-UK born the best fitting model was a negative binomial model with a 
random intercept for year of study entry, adjusting with fixed effects for the change in policy, age and incidence rates in the non-UK born 
(Model 17; Supplement Table S1).
b There was an improvement in the LOOIC score of 0.52 (SE: 2.63) from dropping the change in policy from the model in the UK born cohort and 
a −3.02 (SE: 3.52) improvement in the non-UK born cohort.
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model. No formal threshold for a change in the LOOIC 
was used, with changes in the LOOIC being evaluated 
in the context of their standard error (SE).
The inclusion of the change in policy in the best fitting 
model was tested by refitting the model excluding the 
change in policy and estimating the improvement in 
the LOOIC.
Once the best fitting model had been identified we 
estimated the number of cases prevented, from 2005 
until 2015, for each vaccination programme in the study 
population relevant to that programme (Supplement).
Implementation
R 3.5.2 was used for all analyses [13]. Missing data 
imputation using a GBM was implemented using the 
h2o package [14]. Incidence rates, with 95% CIs, were 
calculated using the epiR package [15]. The brms pack-
age [16] and STAN [17] were used to perform MCMC. 
Models were run until convergence (four chains with a 
burn in of 10,000 and 10,000 sampled iterations each), 
with convergence being assessed using trace plots and 
the R hat diagnostic [17]. All numeric confounders were 
centred and scaled by their standard deviation and age 
was adjusted for using single year of age categories.
Ethical statement
Ethical approval was not required for this study, which 
used anonymised secondary data sources only.
Table 3
Incidence rate ratios of tuberculosis, in the UK born and non-UK born cohorts relevant to the targeted neonatal BCG 
vaccination scheme, using the best fitting modelsa as determined by comparison of the LOOIC, England, 2000–2015
Variable
IRR (95% CrI)
UK born Non-UK born
Policy changeb
Pre-change Reference Reference
Post-change 0.96 (0.82 to 1.14) 0.62 (0.44 to 0.88)
Age
0 Reference Reference
1 1.39 (1.20 to 1.61) 0.49 (0.30 to 0.83)
2 1.24 (1.06 to 1.44) 0.49 (0.30 to 0.80)
3 1.21 (1.03 to 1.41) 0.42 (0.26 to 0.68)
4 0.90 (0.76 to 1.06) 0.41 (0.25 to 0.66)
5 0.89 (0.75 to 1.06) 0.27 (0.16 to 0.45)
Incidence
UK born incidence rate (per standard deviation) 1.12 (1.06 to 1.18) NA
Non-UK born incidence rate (per standard deviation) NA 1.25 (1.04 to 1.51)
Year of study eligibility, group level
Intercept (standard deviation) 1.13 (1.04 to 1.26) NA
Year of study eligibility, individual level
2000 0.83 (0.68 to 0.99) NA
2001 0.93 (0.79 to 1.07) NA
2002 1.08 (0.95 to 1.28) NA
2003 1.07 (0.93 to 1.26) NA
2004 1.12 (0.97 to 1.32) NA
2005 1.02 (0.89 to 1.17) NA
2006 1.02 (0.89 to 1.17) NA
2007 0.97 (0.83 to 1.11) NA
2008 1.01 (0.88 to 1.15) NA
2009 1.01 (0.88 to 1.16) NA
2010 0.98 (0.85 to 1.13) NA
BCG: Bacillus Calmette–Guérin; CrI: credible interval; IRR: incidence rate ratio; LOOIC: leave one out cross validation information criterion; SE: 
standard error; NA: not applicable (i.e. model terms were not included in the given cohort); UK: United Kingdom.
a The best fitting model for the UK born was a Poisson model with a random intercept for year of study entry, adjusting with fixed effects 
for the change in policy, age and incidence rates in the UK born (Model 16; Supplement Table S1). For the non-UK born a negative 
binomial model was the best fit, adjusting with fixed effects for the change in policy, age and incidence rates in the non-UK born 
(Model 8; Supplement Table S1).
b There was an improvement in the LOOIC score of 0.92 (SE: 1.07) from dropping the change in policy from the model in the UK born cohort and 
a −3.45 (SE: 4.63) improvement in the non-UK born cohort.
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Results
Descriptive analysis
During the study period, there were 114,820 notifica-
tions of TB in England, of which 93% (106,765/114,820) 
had their birth status recorded. Of notifications with 
a known birth status 27% (29,096/106,765) were UK 
born, while among notification with an imputed birth 
status, 33% (2,634/8,055) were UK born. Trends in 
incidence rates varied by age group and UK birth sta-
tus (Supplement). During the study period, there were 
1,729 UK born cases and 2,797 non-UK born cases in 
individuals relevant to the universal school scheme 
and 1,431 UK born cases and 238 non-UK born cases 
relevant to the targeted neonatal scheme, who fit 
our age criteria. Univariable evidence for differences 
between mean incidence rates before and after the 
change in BCG policy in the UK born was weak. In 
the non-UK born incidence rates were lower after the 
change in BCG policy in both the cohort relevant to the 
universal school-age scheme and the cohort relevant 
to the targeted neonatal scheme (Figure).
Adjusted estimates of the effects of the change 
in policy on school-age children
In the UK born cohort relevant to universal vaccination 
there was some evidence across all models adjusting 
for age, that ending the scheme was associated with 
a modest increase in TB rates (Supplement Table S2). 
Using the LOOIC goodness of fit criteria, the best fitting 
model was found to be a negative binomial model that 
adjusted for the change in policy, age and incidence 
rates in the UK born (Table 2). In this model there was 
some evidence of an association between the change 
in policy and an increase in incidence rates in those 
at school age who were UK born, with an IRR of 1.08 
(95%CrI: 0.97 to 1.19). Dropping the change in policy 
from the model resulted in a small decrease in the 
LOOIC (0.52; SE: 2.63) but the change was too small, 
with too large a SE, to conclusively state that exclud-
ing the change in policy from the model improved the 
quality of model fit. We found that it was important 
to adjust for UK born incidence rates, otherwise the 
impact from the change in BCG vaccination policy was 
overestimated.
For the comparable non-UK born cohort who were rel-
evant to the universal vaccination there was evidence, 
in the best fitting model, that ending the scheme 
was associated with a decrease in incidence rates 
(IRR: 0.74; 95%CrI: 0.61 to 0.88). The best fitting model 
was a negative binomial model, which adjusted for the 
change in policy, age, incidence rates in the non-UK 
born and year of eligibility as a random effect (Table 
2). We found omitting change in policy from the model 
resulted in poorer model fit (LOOIC increase of 3.02; 
SE: 3.52), suggesting that the policy change was an 
important factor explaining changes in incidence rates, 
after adjusting for other covariates.
All models that adjusted for incidence rates in the 
UK born or non-UK born estimated similar IRRs 
(Supplement Table S3).
Adjusted estimates of the effect of the change 
in policy in those relevant to the targeted 
neonatal programme
For the UK born cohort relevant to the targeted neona-
tal vaccination programme, the evidence of an associa-
tion, across all models, was mixed and CrIs were wide 
compared with models for the UK born cohort relevant 
to the universal school-age vaccination programme 
(Supplement Table S4). The best fitting model was a 
Poisson model, which adjusted for the change in policy, 
age, UK born incidence rates and year of study entry 
with a random effect (Table 3). In this model, there was 
weak evidence of an association between the change in 
BCG policy and a decrease in incidence rates in UK born 
neonates, with an IRR of 0.96 (95%CrI: 0.82 to 1.14). 
Table 4
Estimated number of cases prevented, from 2005 until 2015, for each vaccination programme in the study population 
relevant to that programme, using the best fitting model for each cohort, England, 2000–2015
Vaccination programme Birth status Cases prevented (95% CrI) Notified cases
Universal school-age 
 
(vaccination at 14 yearsa)
All −291 (24 to −571) 2,364
UK born 76 (188 to −26) 969
Non-UK born −367 (−165 to −546) 1,395
Targeted high-risk neonates 
 
(vaccination at birth)
All 94 (−81 to 310) 906
UK born 30 (−95 to 173) 800
Non-UK born 65 (14 to 137) 106
Change in policyb
All 385 (−105 to 881) 3,270
UK born −46 (−284 to 199) 1,769
Non-UK born 431 (179 to 682) 1,501
CrI:  credible interval; UK: United Kingdom.
a In effect, vaccination was implemented across a school year (hence in 13 and 14 year olds) but for the synthetic cohort used in this study, 
vaccination at 14 years of age was used as an entry criterion.
b Estimated total number of cases prevented due to the change in vaccination policy in 2005.
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There was weak evidence to suggest that dropping the 
change in policy from this model improved the quality 
of the fit, with an improvement in the LOOIC score of 
0.92 (SE: 1.07). This suggests that the change in policy 
was not an important factor for explaining incidence 
rates, after adjusting for covariates. Models, which 
also adjusted for non-UK born incidence rates esti-
mated that the change in policy was associated with 
no change in incidence rates in the relevant cohort of 
neonates (Supplement).
For the comparable non-UK born cohort who was rel-
evant to the targeted neonatal vaccination programme 
there was evidence, across all models, that change in 
policy was associated with a large decrease in inci-
dence rates (IRR: 0.62; 95%CrI: 0.44 to 0.88) in the best 
fitting model (Table 3). The best fitting model was a 
negative binomial model that adjusted for the change 
in policy, age, and non-UK born incidence rates (Table 
3). All models for this cohort, which at least adjusted 
for age, estimated comparable effects of the change in 
policy (Supplement Table S5).
Magnitude of the estimated impact of the 
change in Bacillus Calmette–Guérin policy
We estimate that the change in vaccination policy was 
associated with preventing 385 (95%CrI:  −105 to 881) 
cases from 2005 until the end of the study period in 
the directly impacted populations after 5 years of fol-
low-up (Table 4). The majority of the cases prevented 
were in the non-UK born, with cases increasing slightly 
overall in the UK born. This was due to cases increas-
ing in the UK born at school age despite a decrease in 
UK born neonates, although both these estimates had 
large CrIs. 
Discussion
In the non-UK born we found evidence of an associa-
tion between the change in BCG policy and a decrease 
in TB incidence rates in both those at school age and 
neonates, after 5 years of follow-up. We found some 
evidence that the change in BCG policy was associated 
with a modest increase in incidence rates in the UK born 
population who were relevant to the universal school-
age scheme and weaker evidence of a small decrease 
in incidence rates in the UK born population relevant to 
the targeted neonatal scheme. Overall, we found that 
the change in policy was associated with preventing 
385 (95%CrI:  −105 to 881) cases in the study popula-
tion, from 2005 until the end of the study period, with 
the majority of the cases prevented in the non-UK born.
We were unable to estimate the impact of the change 
in BCG policy after 5 years post vaccination, so both our 
estimates of the positive and negative consequences 
are likely to be underestimates of the ongoing impact. 
Tuberculosis is a complex disease and the BCG vaccine 
is known to offer imperfect protection, which has been 
shown to vary both spatially and with time since vacci-
nation [18,19]. By focusing on the impact of the change 
in policy on the directly affected populations within a 
short period of time and by employing a multi-model 
approach we have limited the potential impact of these 
issues. Our study was based on a routine observa-
tional dataset (ETS), and a repeated survey (LFS) both 
of which may have introduced bias. While the LFS is 
a robust data source, widely used in academic stud-
ies [20-22], it is susceptible to sampling errors par-
ticularly in the young and in the old, which may have 
biased the estimated incidence rates. As the ETS is 
a routine surveillance system some level of missing 
data are inevitable. However, the UK birth status was 
relatively complete (93%) and we imputed missing 
values using an approach, which accounted for miss-
ing not at random mechanisms captured by variables 
included in the imputation model. We were unable to 
adjust for known demographic risk factors for TB, nota-
bly socioeconomic status [23,24] and ethnicity [23-25]. 
However, this confounding is likely to be mitigated by 
our use of multiple cohorts and our adjustment for inci-
dence rates in the UK born and non-UK born. Finally, 
we have assumed that the effect we have estimated for 
the change in BCG policy is due to the changes in BCG 
vaccination policy as well as other associated changes 
in TB control policy, after adjusting for hypothesised 
confounders. However, there may have been additional 
policy changes, which we have not accounted for.
While little work has been done to assess the impact 
of the 2005 change in BCG vaccination, several other 
studies have estimated the impact of changing BCG 
vaccination policy, although typically only from univer-
sal vaccination of neonates to targeted vaccination of 
high-risk neonates. A previous study in Sweden found 
that incidence rates in Swedish-born children increased 
after high-risk neonatal vaccination was implemented 
in place of a universal neonatal programme. This corre-
sponds with our finding that introducing neonatal vac-
cination had little impact on incidence rates in UK born 
neonates. Theoretical approaches have indicated that 
targeted vaccination of those at high risk may be opti-
mal in low incidence settings [26]. Our study extends 
this work by also considering the age of those given 
BCG vaccination, although we were unable to estimate 
the impact of a universal neonatal scheme as this has 
never been implemented nationally in England. It has 
previously been shown that targeted vaccination pro-
grammes may not reach those considered most at risk 
[27]. Our findings may support this view as we observed 
only a small decrease in incidence rates in UK born 
neonates after the introduction of the targeted neona-
tal vaccination programme. Alternatively, the effective-
ness of the BCG in neonates, in England, may be lower 
than previously thought as we only observed a small 
decrease in incidence rates, while a previous study 
estimated BCG coverage at 68% (95%CI: 65% to 71%) 
among those eligible for the targeted neonatal vaccina-
tion programme [28].
This study indicates that the change in England’s 
BCG vaccination policy was associated with a modest 
increase in incidence in the UK born who were relevant 
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to the school-age vaccination programme, and with a 
small reduction in incidence in the UK born who were 
relevant to the high-risk neonatal vaccination pro-
gramme, although both these estimates had wide CrIs. 
We found stronger evidence of an association between 
the change in policy and a decrease in incidence rates 
in the non-UK born populations relevant to both pro-
grammes. This suggests that the change of vaccination 
policy to target high-risk neonates may have resulted 
in an increased focus on high-risk non-UK born individ-
uals who may not have been the direct targets of the 
vaccination programme. Further validation is required 
using alternative study designs, but this result should 
be taken into account when vaccination policy changes 
are being considered. Our results should be interpreted 
carefully, especially in the non-UK born, as we could 
not fully rule out the impact of other TB control meas-
ures that may have been changed at the same time as 
vaccination policy. The severity of TB is known to dif-
fer across age groups, with children having a higher 
incidence of TB meningitis, which can be severe, com-
pared with other age groups [1]. This variation should 
also be considered when evaluating these results.
It is well established that interventions against infec-
tious diseases, such as TB, should be evaluated not 
only for their direct effects but also for future indi-
rect effects via ongoing transmission. Statistical 
approaches such as those used in this paper are not 
appropriate for capturing these future indirect effects, 
and instead dynamic disease models should be used. 
In addition, this study could not evaluate the impact of 
the neonatal programme on the high-risk population it 
targets, due to a lack of reliable data. Improved cover-
age data for the BCG programme is required to more 
fully evaluate its ongoing impact. As only 5 years of 
follow-up data were available – and BCG vaccination 
has been shown to provide long lasting protection in 
the UK – repeating this study once more data are avail-
able may alter the findings [29]. For this reason, this 
study has been implemented with reproducibility in 
mind – please see the code reference below for details. 
Finally, the results from this study could be combined 
with estimates of the impact of TB disease, stratified 
by age, to give an estimate of the overall impact of 
the change in policy that accounts for the severity of 
disease.
Accessibility of data and programming code
The code used to clean the data used in this paper can be 
found at: DOI: 10.5281/zenodo.2551555.
The code for the analysis contained in this paper can be 
found at: DOI: 10.5281/zenodo.2583056.
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